Pharmaceutical

EMA CHMP recommends Takeda’s Hyqvia for CIDP treatment

The EMA CHMP recommended granting approval for Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy.

Dec 18, 2023 - 10:51
EMA CHMP recommends Takeda’s Hyqvia for CIDP treatment
The EMA CHMP recommended granting approval for Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy.
Read the original article

Tags:

Previous Article

CymaBay seeks FDA approval for primary biliary cholangitis therapy

Next Article

FDA backs Astellas-Pfizer’s Padcev with Keytruda for urothelial cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: The apparent poisoning of schoolgirls is just one part of Iran’s health crisis

Opinion: The apparent poisoning of schoolgirls is just ...

May 1, 2023

Astellas and PeptiDream enter protein degrader discovery deal

Astellas and PeptiDream enter protein degrader discover...

Jul 25, 2023

STAT+: Pharmalittle: We’re reading about GLP-1 drugs’ safety, Novartis nixing a deal, and more

STAT+: Pharmalittle: We’re reading about GLP-1 drugs’ s...

Jan 12, 2024